A director at Medtronic Plc sold 30,000 shares at 101.948USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Three Directors at Wolverine World Wide Inc bought/maiden bought 33,250 shares at between 15.770USD and 15.880USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the co...
Moody's Ratings (Moody's) upgraded Wolverine World Wide, Inc.'s (Wolverine) ratings, including the corporate family rating (CFR) to B2 from B3, probability of default rating (PDR) to B2-PD from B3-PD, and senior unsecured global notes rating to B3 from Caa2. The speculative grade liquidity rating (S...
Two Directors at J M Smucker Co sold/gave away 13,229 shares at between 0.000USD and 108.110USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Beazer Homes USA, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 15 September 2025 in which we reassessed the appropriateness of the ratings in the c...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.